Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022
Pembrolizumab shows durable efficacy in sorafenib-treated advanced HCC
Pembrolizumab has demonstrated durable efficacy and a manageable adverse event (AE) profile in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib in a 5-year follow-up of the KEYNOTE-224 study.
Pembrolizumab shows durable efficacy in sorafenib-treated advanced HCC
14 Sep 2022
CNS metastasis worsens survival in endometrial cancer
Among patients with endometrial cancer (EC), central nervous system metastasis (CNSm) is strongly associated with poor prognoses and survival outcomes, a recent study has found.
CNS metastasis worsens survival in endometrial cancer
12 Sep 2022
Bladder-directed heated chemotherapy of no clear benefit in NMIBC
In patients with intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), intravesical chemohyperthermia (CHT) does not translate to better cancer control than standard room-temperature chemotherapy, according to a recent phase II study HIVEC-II.
Bladder-directed heated chemotherapy of no clear benefit in NMIBC
12 Sep 2022
Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer
In the treatment of patients with HER2-positive locally advanced breast cancer, adding pyrotinib to trastuzumab plus chemotherapy in the neoadjuvant setting yields high response rates while being safe, according to the results of NeoATP trial.
Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer
12 Sep 2022
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
11 Sep 2022
Spleen pull-out lymph node dissection safe for gastric cancer
The use of spleen pull-out lymph node dissection in the splenic hilum is both safe and feasible for patients with gastric cancer undergoing radical gastrectomy, a recent study has found.
Spleen pull-out lymph node dissection safe for gastric cancer
11 Sep 2022
Malnutrition tied to poor survival in metastatic cervical cancer
Low serum albumin levels appear to be an important risk factor for poor survival outcomes among patients with metastatic cervical cancer, a recent study has found.